Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity

Author's Avatar
May 23, 2023

Immunome%2C+Inc.+%28Nasdaq%3A+IMNM%29, a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled “IL-38+blockade+induces+anti-tumor+immunity+by+abrogating+tumor-mediated+suppression+of+early+immune+activation,” in the peer-reviewed journal mAbs. The data in the article demonstrates that antibody-based targeting of IL-38 reactivates the immunostimulatory anti-tumor mechanisms within the tumor microenvironment in preclinical testing.